A questionnaire survey on the efficacy of various treatments for dyskinetic cerebral palsy due to preterm bilirubin encephalopathy.


Journal

Brain & development
ISSN: 1872-7131
Titre abrégé: Brain Dev
Pays: Netherlands
ID NLM: 7909235

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 15 10 2019
revised: 06 01 2020
accepted: 21 01 2020
pubmed: 18 2 2020
medline: 3 11 2020
entrez: 18 2 2020
Statut: ppublish

Résumé

Preterm children with severe dyskinetic cerebral palsy due to bilirubin encephalopathy often suffer from marked generalised hypertonus as they age. We performed a questionnaire survey to investigate patient-reported outcomes of treatments for improving their activities of daily life. A mail questionnaire was administered to the caregivers of 67 children with preterm bilirubin encephalopathy aged >4 years. We asked about the type of treatments they received and their efficacy using a five-point subjective scale for the following five domains: motor function, postural stability, sleep, pain, and care burden. The names of oral drugs and their efficacies were also explored. The response rate of the questionnaires was 62.7% (42/67), and we analysed the results from 41 validated cases. All children underwent rehabilitation. A total of 30 children received oral drugs, 22 botulinum toxin, 12 orthopaedic surgery, and 3 intrathecal baclofen. Each of these treatments was subjectively reported to be effective in more than half of the recipients for each of the five domains, whereas 23 (56%) required more than two types of treatments other than rehabilitation. Chlordiazepoxide was the most commonly used oral drug, by 28 children (68%), and was discontinued in 7 patients (25%) only. In the sleep domain, the rate of a positive effect was significantly higher for oral drugs (92.7%) than the other treatments (p < 0.01). All treatments were partially effective, but their appropriate combination based on a multidisciplinary approach is essential for muscle tone management in children with preterm bilirubin encephalopathy.

Identifiants

pubmed: 32063420
pii: S0387-7604(20)30032-2
doi: 10.1016/j.braindev.2020.01.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

322-328

Informations de copyright

Copyright © 2020 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Auteurs

Yukihiro Kitai (Y)

Department of Pediatric Neurology, Bobath Memorial Hospital, Osaka, Japan. Electronic address: kitai@omichikai.or.jp.

Satori Hirai (S)

Department of Pediatric Neurology, Bobath Memorial Hospital, Osaka, Japan.

Naomi Okuyama (N)

Department of Pediatric Neurology, Bobath Memorial Hospital, Osaka, Japan.

Mika Hirotsune (M)

Department of Pediatric Neurology, Bobath Memorial Hospital, Osaka, Japan.

Shizuka Nishimoto (S)

Department of Pediatric Neurology, Bobath Memorial Hospital, Osaka, Japan.

Satoshi Mizutani (S)

Department of Pediatric Neurology, Osaka Women's and Children's Hospital, Izumi, Japan.

Akihisa Okumura (A)

Department of Pediatrics, Aichi Medical University, Nagakute, Japan.

Satoko Kumada (S)

Department of Neuropediatrics, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.

Hiroshi Arai (H)

Department of Pediatric Neurology, Bobath Memorial Hospital, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH